- Home
- CRVS vs CCCC Comparison
CRVS vs CCCC Comparison
Compare CRVS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- CCCC
- Stock Information
- Founded
- CRVS 2014
- CCCC 2015
- Country
- CRVS United States
- CCCC United States
- Employees
- CRVS N/A
- CCCC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- CCCC Health Care
- Exchange
- CRVS Nasdaq
- CCCC Nasdaq
- Market Cap
- CRVS 206.5M
- CCCC 244.9M
- IPO Year
- CRVS 2016
- CCCC 2020
- Fundamental
- Price
- CRVS $3.63
- CCCC $1.54
- Analyst Decision
- CRVS Strong Buy
- CCCC Buy
- Analyst Count
- CRVS 3
- CCCC 4
- Target Price
- CRVS $15.67
- CCCC $12.50
- AVG Volume (30 Days)
- CRVS 906.6K
- CCCC 1.3M
- Earning Date
- CRVS 05-05-2025
- CCCC 05-07-2025
- Dividend Yield
- CRVS N/A
- CCCC N/A
- EPS Growth
- CRVS N/A
- CCCC N/A
- EPS
- CRVS N/A
- CCCC N/A
- Revenue
- CRVS N/A
- CCCC $35,584,000.00
- Revenue This Year
- CRVS N/A
- CCCC N/A
- Revenue Next Year
- CRVS N/A
- CCCC $36.31
- P/E Ratio
- CRVS N/A
- CCCC N/A
- Revenue Growth
- CRVS N/A
- CCCC 71.44
- 52 Week Low
- CRVS $1.43
- CCCC $1.09
- 52 Week High
- CRVS $10.00
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- CRVS 55.04
- CCCC 46.45
- Support Level
- CRVS $3.15
- CCCC $1.09
- Resistance Level
- CRVS $3.78
- CCCC $1.74
- Average True Range (ATR)
- CRVS 0.25
- CCCC 0.18
- MACD
- CRVS 0.12
- CCCC 0.09
- Stochastic Oscillator
- CRVS 87.90
- CCCC 69.47
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.